cyproterone and Lung-Neoplasms

Prostate carcinoma is one of the most frecuent cancers in men. Significant numbers of patients have regional lymph node and bone metastases during the course of the disease. Mediastinal lymphadenopathy and cutaneous metastases are uncommon and signify well-advanced disease. We report the case of a patient with prostate cancer who develops mediastinal lymphadenopathy, pulmonary nodules and cutaneous metastases 8 years after the diagnosis.

Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid

We report an unusual case of pulmonary lymphangioleiomyomatosis in a menopaused woman who had been taking estrogen hormone replacement therapy for several years. The characteristic feature of this uncommon disease is a proliferation of non-tumoral abnormal smooth muscle cells within the alveolar walls, and around the bronchi, lymph nodes and blood vessels. About twenty cases of pulmonary lymphangioleiomyomatosis have been described in menopaused women, who generally were taking estrogen hormone replacement therapy. This subpopulation does not appear to present any particular clinical, functional or radiographic features.

Topics: Androgen Antagonists; Biopsy; Chylothorax; Cyproterone; Estradiol; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Lung; Lung Neoplasms; Lymphangioleiomyomatosis; Megestrol; Menopause; Middle Aged; Norpregnadienes; Progesterone Congeners; Radiography, Thoracic; Time Factors; Tomography, X-Ray Computed

The presentation of prostatic carcinoma with pulmonary metastases is unusual. The patient reported here presented with nodular lung metastases from an unknown primary site and 3.5 years later became symptomatic with a prostatic carcinoma. Subsequent hormonal therapy led to radiological regression of the pulmonary metastases. This case report demonstrates the progression of asymptomatic prostatic lung metastases with time and their response to delayed hormonal therapy, which is discussed.

Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cyproterone; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasms, Unknown Primary; Prostatic Neoplasms; Remission Induction

A patient is described who presented with left upper lobe collapse due to endobronchial metastatic prostate carcinoma. Treatment with the oral antiandrogen cyproterone acetate resulted in resolution of the occluding endobronchial carcinoma and lobar re-expansion.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Humans; Lung; Lung Neoplasms; Male; Prostatic Neoplasms; Pulmonary Atelectasis

Three male patients of 55, 63 and 71 years of age, with metastatic breast cancer, were treated with cyproterone acetate. Two patients showed complete remission, one lasting 21 months, another 51+ months and a third achieved partial remission lasting 9 months. These results suggest that cyproterone acetate may be useful in the treatment of advanced male breast cancer.

Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cyproterone; Cyproterone Acetate; Drug Evaluation; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis

Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Androgen Antagonists; Bone Neoplasms; Carcinoma; Cyproterone; Estrogens; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pregnadienes; Prostatic Neoplasms

Topics: Bone Neoplasms; Castration; Cyproterone; Estrogens; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Metastasis; Prostatic Neoplasms; Spinal Cord Neoplasms